Targeting cancer stem cells via integrin β4

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Integrins, like integrin beta 4 (ITGB4), are crucial for cell interactions and signaling, making them attractive targets for cancer therapy.
• Cancer stem cells (CSCs) are resistant to conventional treatments and drive tumor metastasis and relapse.
• ITGB4 is expressed on CSCs in models of metastatic mammary tumors and head and neck squamous cell carcinoma.

Purpose of the Study:

• To investigate the efficacy of targeting ITGB4 on CSCs using immunological approaches.
• To evaluate the potential of ITGB4-targeted therapies in reducing tumor growth, metastasis, and improving treatment outcomes.

Main Methods:

• Two immunological strategies were employed: ITGB4 protein-pulsed dendritic cell (ITGB4-DC) vaccination and anti-CD3/anti-ITGB4 bispecific antibody (ITGB4 BiAb)-armed T cell adoptive transfer.
• These therapies were tested in 4T1 mouse metastatic mammary tumor and SCC7 head and neck squamous cell carcinoma models.
• The combination of ITGB4-targeted approaches with anti-PD-L1 immunotherapy was also assessed.

Main Results:

• Both ITGB4-targeted therapies successfully reduced ITGB4-expressing CSCs.
• Local tumor growth and lung metastasis were inhibited, mediated by ITGB4-specific immune responses.
• Combining ITGB4-targeted therapies with anti-PD-L1 immunotherapy significantly enhanced treatment efficacy.
• Increased serum concentrations of IFN-γ and IL-6 were observed.

Conclusions:

• ITGB4 serves as a viable immunological target for CSCs.
• ITGB4-targeted therapies demonstrate therapeutic potential across diverse tumor types expressing high ITGB4 levels.
• Further research into ITGB4-targeted strategies, potentially including cytokine analysis, is warranted.